Portfolio (Quarterly)
Guide ↗
Remedium Capital Partners, LLC
· CIK 0002104501| # | Ticker | Company | Sector | Shares | Value ↓ | % Port | Chg Shares | Chg % | Period Price ① | Since Period ① |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA | Oruka Therapeutics Inc | Healthcare | 1,565,661.0 | $149.0M | 32.99% | -323K | -17.1% | $95.17 | +7.0% |
| 2 | SYRE | Spyre Therapeutics Inc | Healthcare | 1,464,169.0 | $130.0M | 28.78% | -443K | -23.2% | $88.78 | +20.9% |
| 3 | — | Apogee Therapeutics Inc | — | 586,691.0 | $77.9M | 17.24% | +3K | +0.5% | $132.73 | — |
| 4 | — | Damora Therapeutics Inc | — | 2,045,473.0 | $53.2M | 11.78% | — | — | $26.01 | — |
| 5 | JBIO | Jade Biosciences Inc | Healthcare | 1,577,750.0 | $35.1M | 7.76% | — | — | $22.22 | -1.7% |
| 6 | — | Crescent Biopharma Inc | — | 361,250.0 | $6.5M | 1.44% | NEW | — | $18.00 | — |
① Period Price is the implied market price on the last day of the reporting period, calculated as reported value ÷ shares held. It is not the fund's purchase price or cost basis — the fund may have initiated or added to the position at any point during the quarter at a different price. Since Period shows the price change from that quarter-end snapshot to today's last price — it reflects stock movement after the report date, not the fund's actual return.
Sector Allocation
Healthcare
100.0%